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Abstract 
Objective: Experimental evidence has suggested that drugs that enhance cannabinoid type-1 (CB1) receptor activity may induce 
anxiolytic and antidepressant effects, whilst the opposite has been reported with antagonists. Thus, the objective of the present review is 
to discuss the potential psychiatric side-effects of CB1 receptor antagonists, such as rimonabant, which has been recently marketed in 
several countries for the treatment of smoking cessation, obesity and associated metabolic disorders. Method: Literature searches were 
performed in PubMed and SciELO databases up to February 2009. The terms searched were “obesity”, “rimonabant”, “cannabinoids”, 
“unwanted effects”, “diabetes”, “smoking cessation” and “side-effects”. Results: Clinical trials have revealed that rimonabant may 
promote weight loss in obese patients, although it may also induce symptoms of anxiety and depression. Discussion: Patients taking 
CB1 receptor antagonists should be carefully investigated for psychiatric side-effects. These drugs should not be prescribed for those 
already suffering from mental disorders. Nevertheless, the development of new compounds targeting the endocannabinoid system for 
the treatment of several conditions would be necessary and opportune.
Descriptors: Cannabinoids; Drug effects; Anxiety; Depression; Obesity
Resumo
Objetivo: Evidência experimental sugere que drogas que aumentam a atividade dos receptores canabinóides tipo 1 (CB1) podem induzir 
efeitos ansiolíticos ou antidepressivos, enquanto que o oposto tem sido relatado com antagonistas. Assim, o objetivo da presente revisão é 
discutir os potenciais efeitos-colaterais psiquiátricos de antagonistas do receptor CB1, como o rimonabanto, que foi recentemente liberado 
para comercialização em diversos países para o tratamento do tabagismo, obesidade e de desordens metabólicas associadas. Método: 
Foi realizada uma busca na literatura no PubMed e Scielo até fevereiro de 2009, com os termos “obesity”, “rimonabant”, “cannabinoids”, 
“unwanted effects”, “diabetes” , “smoking cessation” e “side effects”. Resultados: Ensaios clínicos revelaram que o rimonabanto pode 
produzir perda de peso em pacientes obesos, embora também possa induzir sintomas de ansiedade e depressão. Discussão: Pacientes 
tomando antagonistas do receptor CB1 devem ser cuidadosamente examinados quanto aos efeitos-colaterais psiquiátricos. Estas drogas 
não devem ser prescritas a indivíduos que já sofrem de transtornos mentais. Entretanto, o desenvolvimento de novos compostos que 
atuem no sistema endocanabinóide para o tratamento das mais diversas condições parece necessário e oportuno.
Descritores: Canabinóides; Efeitos de drogas; Ansiedade; Depressão; Obesidade
Submitted: November 20, 2008
Accepted: March 3, 2009
145
Rev Bras Psiquiatr. 2009;31(2):145-53
Side-effects of rimonabant 
Rev Bras Psiquiatr. 2009;31(2):145-53
146
Introduction
Rimonabant (Sanofi-Aventis®), a cannabinoid receptor antagonist/
inverse agonist, has reached the market as a drug for the treatment 
of obesity in several countries. The approval for its use was based on 
few clinical trials claiming that it is an effective and safe anti-obesity 
drug1-6 with a potential for aiding smoking cessation.7 However, 
this should be interpreted with caution considering the limited 
information on the long-term effects. Furthermore, clinical studies 
have revealed that this drug may induce significant psychiatric side-
effects, namely anxiety and depression. Actually, this was expected 
based on data available from animal models.
A license for rimonabant for weight reduction indication was 
received from the European Medicines Agency (EMEA) under 
the brand name Accomplia® in June 2006. In April 26th, 2007, 
the Brazilian Medicines Agency (Agência Nacional de Vigilância 
Sanitária, ANVISA) approved this compound for the same indication. 
In June 2007, the FDA refused to follow the EMEA and ANVISA 
and denied a license for weight reduction, as they had done a year 
earlier for smoking, until further trials gave positive assurances on 
side-effects.8 In reviewing postmarketing surveillance data on the 
drug, the EU’s Committee for Medicinal Products for Human Use 
found that rimonabant doubled the risk of psychiatric disorders 
in obese or overweight patients taking the drug, leading to an 
amendment to the Summary of Product Characteristics in August 
2007. This fact culminated in the EMEA asking for rimonabant 
to be withdrawn from sale in October 2008, pending further trial 
results. An ANVISA resolution on November 3rd recommended that 
the company suspend sales and manipulation of the drug in Brazil 
due to safety concerns. Sanofi-Aventis® thus complied and withdrew 
rimonabant simultaneously from all other non-European Union (EU) 
markets, and on November 5th the manufacturer announced that 
they had discontinued all requested trial work on the drug.9
The withdrawal of rimonabant reflects the problems of premature 
approval of drugs. Obesity, associated metabolic disorders and 
tobacco dependence are major public health problems for which 
treatment options are limited. Particularly in this field, innovative 
pharmacological approaches often raise hopes in health professionals 
and in the general public, since they would have a huge impact 
in terms of public health and preventive medicine. However, novel 
drugs may not necessarily match such expectations, mainly due to 
low efficacy and poor safety profile. Thus, the objective of the present 
review is to discuss the side-effects and the psychiatric relevance of 
rimonabant and substances that act by similar mechanisms.
Method
For evaluating the psychiatric side-effects of rimonabant and 
cannabinoid receptor antagonists or inverse agonists, a literature 
search was performed in PubMed and SciELO up to February 2009. 
The terms entered were “obesity”, “rimonabant”, “cannabinoid”, 
“unwanted effects”, “diabetes”, “smoking cessation”, and “side-
effects”, which retrieved 71 articles. Inclusion criteria were usage 
of the English language and employing human beings as subjects, 
resulting in the inclusion of 49 studies. In addition, an extensive 
literature was consulted for the introduction on the endocannabinoid 
system and its role in anxiety and depression.
Results
1. The endocannabinoid system
The herb Cannabis sativa has been used for medical purpose, 
and as a drug of abuse, for 4000 years.10-12 However, only in the 
middle of the 20th century its constituents were identified, with the 
chemical characterization of ∆9-tetrahydrocannabinol (∆9-THC) and 
other substances. The pharmacology of ∆9-THC has been largely 
elucidated and a specific receptor identified, the cannabinoid 
type 1 (CB1) receptor, responsible for the brain effects of cannabis.13 
The existence of receptors specific for cannabinoids suggested that 
endogenous cannabinoid-like substances should also be present in 
the brain. Accordingly, the arachidonic acid derivates 2-arachidonoyl 
ethanolamide (anandamide, after the Sanskrit word ananda, 
meaning “bliss”) and 2-arachidonoyl glycerol (2-AG) were identified 
as endogenous agonists at the cannabinoid receptor, hence the 
name endocannabinoids.14,15 In addition, a second receptor (CB2) 
has been characterized, mainly located in the immune system.13 
Endocannabinoids are atypical neurotransmitters released from 
postsynaptic neurons and later re-internalized through a putative 
uptake process. This is followed by hydrolysis by the enzymes fatty 
acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), 
which break down anandamide and 2-AG, respectively.13 The 
endocannabinoids, their receptors and the enzymes for synthesis 
and hydrolysis constitute the endocannabinoid system (Figure 1).
This system is widely distributed in the brain. CB1 receptors are 
particularly enriched in regions possibly responsible for processing 
emotions, such as hippocampus, amygdala, periaqueductal gray, 
prefrontal cortex and hypothalamus.16 This distribution provides 
a neuroanatomical basis for the effects of cannabis, which can 
induce states reported as relaxation, well-being and reduced 
anxiety.17 Based on experimental evidence, other physiological 
functions have been attributed to the endocannabinoid system. 
For instance, this system seems to be relevant for motor responses, 
as revealed by the dense expression of CB1 receptors in the basal 
ganglia and cerebellum and by the sedative effects of cannabinoids. 
CB1 receptors also mediate analgesic effects, an anciently known 
property of cannabis.18 Finally, endocannabinoids are also relevant 
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for motivation for food consumption, and an increase in appetite is 
a widely known effect of cannabis.19,20
These proposed functions of endocannabinoids were initially 
inferred from their distribution in the brain and from the effects 
of ∆9-THC or its synthetic counterparts, such as nabilone. The 
relevance of the endocannabinoid system was further clarified after 
the synthesis of the first CB1 receptor antagonist, SR141716A or 
rimonabant.21,22 This drug was developed by Sanofi-Aventis® and 
proved to be an invaluable pharmacological tool for studying the 
functions of endocannabinoids due to its selectivity and oral activity. 
Rimonabant was able to block the effects of cannabinoids in vitro 
and in experimental animals,21,22 inducing behavioral effects that 
will be discussed later. In addition, a study with humans showed 
that it was able to block the psychological and cardiovascular effects 
of smoked marijuana.23 Although it may have properties of inverse 
agonists in vitro,24 the in vivo implications of this mechanism remain 
unknown. Thus, for the matter of simplicity, this review will refer to 
this and similar drugs as antagonists.
A well-known effect of cannabis is an increase in appetite. As a 
corollary, studies with laboratory animals revealed that rimonabant 
promote weight loss by reducing food intake and inducing 
peripheral and central effects on fat metabolism.19,20 However, 
preclinical studies with this drug have also unveiled a tonic role for 
endocannabinoids in the modulation of anxiety and depression, as 
discussed below.
2. Role of the endocannabinoid system in anxiety and mood 
states
Cannabis smoking may induce a myriad of changes in mood and 
anxiety-related responses. This may depend on drug, individual 
and environmental factors such as dose, context and frequency of 
use, previous experience and emotional state.25 Whilst variable, the 
effects of low doses are often described as rewarding and relaxing, 
with feelings of “high”, relaxation, reduced anxiety and increased 
sociability.11,17,26
Several works have investigated the effects of ∆9-THC or its 
synthetic counterparts administered to laboratory animals exposed to 
models predictive of anxiolytic-like activity. Obviously, animal models 
do not entirely mimic the complex features of psychiatric disorders. 
However, they can predict the clinical effects of substances and 
provide insights in the biological mechanisms of these diseases.27 
Generally, they are able to reproduce the effects of cannabinoids 
observed in humans. Thus, several authors have reported that, 
similarly to diazepam, ∆9-THC and synthetic cannabinoids induced 
anxiolytic-like effects in laboratory rats and mice.28-31 In addition, 
cannabinoids have also antidepressant-like properties.32
These data suggest that the CB1 receptor may restrain anxiety 
responses and prevent stress-induced alterations in mood states. 
Further supporting this notion are the effects of drugs that enhance 
the levels of endogenous cannabinoids. Two different processes 
have been explored to increase the brain levels of anandamide, 
namely membrane transport (“uptake”) and hydrolysis. Inhibition 
of anandamide uptake induces anxiolytic- and antidepressant-
like effects in rats,30-35 although the later strategy has not been 
further developed due to the fact that the membrane transporter 
has not been characterized. More explored have been the effects 
on anandamide-hydrolysis. A specific FAAH inhibitor has been 
developed, called URB597. This drug also has anxiolytic- and 
antidepressant-like properties without the sedative effects seen with 
cannabinoids, which directly activate CB1 receptors.30,36-38 Thus, 
endocannabinoids seems to modulate emotional responses and has 
emerged as a potential therapeutic target. 
Experiments with rimonabant and other CB1 receptor antagonists 
have further consolidated this conclusion. Contrary to agonist, these 
drugs induce anxiogenic-like effects in laboratory animals30,38-40 and 
aggravate the consequences of stress.41 In addition, CB1 blockade 
impairs the extinction of fear conditioned to a tone previously paired 
with foot-shock, a model reminiscent of posttraumatic stress.42 
Thus, a set-point may exist in which endocannabinoid could keep 
emotional responses in a normal range and whose disruption may 
lead to anxiety and depression.25 
Despite evidence that an endocannabinoid tonus should be 
maintained, rimonabant has reached the market as an alternative 
for the treatment of obesity. So far, the limited clinical information 
available on the efficacy and safety of this drug are in line with the 
results obtained from animal models. 
3. Therapeutic potential and side-effects of CB1 receptor an-
tagonists
CB1 receptors antagonists have been investigated mainly as 
a potential strategy for treating obesity and associated metabolic 
disorders.19-20 Despite their putative clinical applications, the 
experimental evidence discussed above heralded the notion that 
rimonabant could induce psychiatric effects. This prediction has 
been confirmed by the clinical trials discussed below.
Apart from a few studies, information about the effects of 
rimonabant in humans is still scant. The first clinical trial with 
this drug aimed at assessing the antipsychotic efficacy of four 
investigational compounds.43 Subjects were patients with 
schizophrenia or schizoaffective disorder who received placebo 
(n = 98), rimonabant 20mg (n = 72), a serotonin-2A/2C antagonist 
(n = 74), a neurokinin-3 antagonist (n = 70), a neurotensin-1 
antagonist (n = 69), and haloperidol as a positive control (n = 98). 
Duration was 6 weeks. Only the serotonin-2A/2C and neurokinin-3 
antagonists were better than placebo, though worse than haloperidol. 
No major psychiatric side-effects were reported.
As for the anti-obesity effects, the initial large multicenter, 
randomized, placebo-controlled clinical trials were the Rimonabant 
in Obesity Studies (RIO Studies), which have checked the effects 
of this drug on weight loss, waist circumference and metabolic 
parameters in diverse populations of overweight or obese patients.1-5 
In all cases, patients were also prescribed a hypocaloric diet and 
advised on increased physical activity. Psychiatric disorders were 
exclusion criteria, and side-effects were evaluated by the Hospital 
Anxiety and Depression Scale (HAD), which may be acceptable to 
screen for depression and anxiety in non-psychiatric patients, but it is 
not suitable as a primary outcome measure for depression.44 Finally, 
it should be noticed that all the RIO-Studies were funded by Sanofi-
Aventis®, which holds the patent for rimonabant. The company 
participated in the study design, data collection and analysis, and in 
manuscript preparations.1-5 This company also funded the Strategy 
to Reduce Atherosclerosis Development Involving Administration of 
Rimonabant – The Intravascular Ultrasound Study (STRADIVARIUS), 
which, contrary to the RIO Studies, did include psychiatric patients.6 
The main characteristics of these studies are summarized in Table 
1. In the course of the treatments, many patients have abandoned 
both the RIO and STRADIVARIUS Studies due to general psychiatric 
side-effects, anxiety and depression. The absolute numbers and 
percentages for the groups placebo or rimonabant 20mg are 
presented in Table 2. 
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In the RIO-Europe Study, 1,507 obese patients have taken 
placebo, 5 or 20mg of the drug daily.1 Both doses induced a 
reduction in body weight after one year of treatment, as compared to 
placebo. In addition, the higher dose induced greater improvements 
in several metabolic measures.1 Despite these clinical improvements, 
the authors described psychiatric side-effects as detected by the 
HAD employed to evaluate mood. In some cases, the effects were 
severe, leading patients to abandon the trial (Table 2). An analysis 
of the second year of this study has been published with similar 
outcomes.5 These data are summarized in Table 2.
Concerns on the safety of rimonabant have further increased after 
the RIO-Lipids Study, which for 1 year evaluated the effect on 1,036 
overweight or obese patients with dyslipidemia taking placebo or daily 
doses of 5 or 20mg.2 As in the RIO-Europe Study, the most common 
symptoms leading patients to drop out of the study were depression 
and anxiety (Table 2). Although the percentage of patients leaving the 
trial was similar among the groups, those taking 20mg attributed it 
more to adverse events, mainly anxiety and depression.2
The outcomes of these studies were replicated in the RIO-North 
America Study, which involved 3,045 subjects over 2 years. 
Rimonabant 20mg associated with hypocaloric diet induced a 
significant reduction in body weight in a population of obese 
patients.3 However, the same side-effects present in the former 
studies were reported. Actually, the trial was limited by a high 
dropout rate (Table 2). The author stated that the overall incidence 
of adverse events leading to withdrawal was greater with 20mg, 
mainly due to anxiety and depression.3 
Finally, in the RIO-Diabetes Study, 1,047 overweight or obese 
patients with type 2 diabetes were assigned to placebo or rimonabant 
5 or 20mg/day. Weight loss and improvement of cardiovascular and 
metabolic risk factors were significantly greater after one year in 
both rimonabant groups as compared to placebo.4 Discontinuation 
due to adverse effects was more common in rimonabant-treated 
patients, mainly due to depressed mood disorders (Table 2). 
However, the authors concluded that no serious adverse events 
linked to psychiatric disorders occurred.4
Thus, studies with different populations of obese subjects 
revealed that rimonabant has a potential to induce anxiety and 
depression. Actually, the assumptions of these studies may even 
be conservative. Since psychiatric patients were not included, these 
trials do not entirely mimic the clinical practice and underestimate 
the potential problems to be found with this drug, which might 
eventually be prescribed for patients already suffering from anxiety or 
depression, disorders commonly associated with obesity that could 
be aggravated by such compounds.45,46 In fact, a remarkable report 
by the Advisory Committee of the US Food and Drug Administration 
(FDA) scrutinized the data from the RIO-Studies and raised even 
more concerns over this drug. This report indicated that rimonabant 
significantly increased risk of suicide attempts or ideation and that 
26% of participants taking 20mg had some psychiatric side-effects 
compared to 14% taking placebo. In addition to depression and 
anxiety, there were more cases of irritability, insomnia, stress and 
panic attacks.47 Accordingly, rimonabant has not been approved in 
the USA. In addition, Christensen et al. performed a meta-analysis 
of the four RIO studies, further unveiling that patients receiving 
20mg were 2.5 and 3.0 times more likely to discontinue treatment 
because of depression or depressive symptoms and because 
of anxiety, respectively.48 This meta-analysis also showed that, 
accordingly to the HAD Scale, rimonabant was associated with 
significant increases in anxiety.48 An independent meta-analysis of 
diverse anti-obesity drugs pointed in the same direction.49 Efficacy 
and safety were further analyzed pooling data obtained from a 
total of 5,580 non-diabetic and 1,047 diabetic patients from the 
RIO-Studies.50 With the dose of 20mg, body weight reduction was 
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6.5kg and waist circumference 6.4cm on average in the non-
diabetic population. The authors stated that “serious adverse events 
were infrequent and almost equivalent to placebo”. However, the 
rimonabant 20mg group (2,503 patients) was associated with a 
higher discontinuation due to depressive disorders (1.9%) and 
anxiety (1.0%) as compared to those receiving placebo (1,602 
patients), whose rates of discontinuation were 0.8 and 0.3% for 
depressive and anxiety disorders, respectively.50 
In addition to the RIO-Studies, Sanofi-Aventis® also funded 
the Strategy to Reduce Atherosclerosis Development Involving 
Administration of Rimonabant – The Intravascular Ultrasound 
Study (STRADIVARIUS), a randomized, placebo-controlled clinical 
trial that enrolled 839 patients in North America, Europe and 
Australia6 (Table 1). The authors described a significant effect of 
rimonabant 20mg on weight loss, though not in coronary artery 
disease progression. As for the adverse effects, an extremely relevant 
characteristic of this study was that psychiatric disorders were not 
exclusion criteria, contrary to the RIO-Studies. Thus, it detected 
alarming higher levels of psychiatric side-effects, namely anxiety 
and depression, and may reflect better the potential effects to be 
found in the routine clinical practice, further raising the concerns 
on the safety of rimonabant. Adverse effects for psychiatric disorders 
were statistically significant, 28.4 and 43.4% in the placebo and 
rimonabant 20mg groups, respectively. Anxiety and depression 
have accounted for this difference. Furthermore, the same factors 
significantly led to discontinuation, 3.1 and 9.5% of patients in 
placebo and drug groups, respectively (Table 2).
Recently, Sanofi-Aventis® funded the Study Evaluating 
Rimonabant Efficacy in Drug-Naive Diabetic Patients (SERENADE).51 
In this 6-month, randomized, double-blind, placebo-controlled trial 
of 20mg/day rimonabant, the glucose-lowering efficacy and safety 
of rimonabant monotherapy was assessed in 278 drug-naive type 
2 diabetic patients (Table 1). The SERENADE study was the first 
trial to use A1C as the primary endpoint. Rimonabant monotherapy 
significantly improved glycemic control, body weight (waist 
circumference and weight loss), and lipid profile (triglycerides, and 
HDL cholesterol) in drug-naive type 2 diabetic patients. The safety 
profile of 20mg rimonabant in SERENADE was similar to that in 
the RIO-Diabetes study. The incidence of psychiatric disorders was 
higher with rimonabant versus placebo, and more patients receiving 
rimonabant experienced anxiety (5.8 vs. 3.6%, respectively) or 
depressed mood (5.8 vs. 0.7%, respectively) versus placebo (Table 
2). One patient in the rimonabant group (0.7%) reported suicide 
ideation, judged by the investigator to be a symptom of depressed 
mood; although no cases of attempted or completed suicide were 
reported. The authors raised the need of further studies to better 
establish the benefit-to-risk profile of rimonabant.
Because obesity and tobacco dependence are the two major 
causes of preventable mortality and morbidity in many developed 
countries, a drug to treat both disorders was an exciting prospect.52 
Moreover, it is well-known that smoking cessation rates might be 
improved by combining drugs (such as bupropion or varenicline) 
with nicotine replacement and by reducing postcessation weight 
gain. Therefore, rimonabant was added on nicotine patch to test its 
smoking cessation efficacy in the CIRRUS study.7 In a randomized, 
double-blind, placebo-controlled trial, 755 smokers (15 cigarettes/
day) were given rimonabant (20mg daily) open-label for 9 weeks. 
The 735 participants who completed the first week of treatment 
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were randomized at day 8 (target quit day) to add a nicotine patch 
(n = 369) or placebo patch (n = 366) for 10 weeks (21mg daily 
for 8 weeks plus a 2-week taper). They also received weekly 
smoking counseling and were followed for 24 weeks. The authors 
observed that adding a nicotine patch to rimonabant increased 
smoking cessation rates over rimonabant alone (39.0 vs. 21.3%, 
respectively) in all other efficacy measures. Depression and anxiety-
related adverse events occurred in 32 (4.2%) and 44 (5.8%) 
subjects, respectively; eight (1.1%) and nine (1.2%) subjects 
stopped the drug use due to depression and anxiety, respectively.
The most recently published clinical study with rimonabant is 
the ADAGIO-Lipids trial (An International Study of Rimonabant 
in Dyslipidemia with AtheroGenic Risk in Abdominally Obese 
Patients).53 In this study the authors assessed the effect of 
rimonabant on cardiometabolic risk factors and intra-abdominal 
and liver fat. The ADAGIO-Lipids study was conducted in 799 
patients with abdominal obesity and with the high triglyceride/
low HDL-cholesterol dyslipidemia, who were randomized to 
placebo or rimonabant 20mg/day for 1 year. Rimonabant 20mg 
significantly improved multiple cardiometabolic risk markers and 
induced significant reductions in both intra-abdominal and liver 
fat. The safety profile of rimonabant was consistent and closely 
follows those from the previous studies. Anxiety and depression 
were again the most frequent psychiatric adverse events leading 
to premature treatment discontinuation: nine patients (2.2%) and 
four patients (1.0%) for anxiety; and eight patients (2.0%) and 
five patients (1.3%) for depression, in the rimonabant and placebo 
groups, respectively.
At the time of writing of this review, other clinical trials with 
rimonabant were being conducted (http://clinicaltrials.gov/ct2/
results?term=rimonabant, accessed February 19th, 2009). Some 
of them are: Comprehensive Rimonabant Evaluation Study of 
Cardiovascular ENDpoints and Outcomes (CRESCENDO Study); 
Atherosclerosis Underlying Development Assessed By Intima-Media 
Thickness In Patients On Rimonabant (AUDITOR Study); Visceral Fat 
Reduction Assessed by CT-Scan on Rimonabant (VICTORIA Study); 
Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic 
Patients (ARPEGGIO Study); Rimonabant In Prediabetic Subjects 
To Delay Onset Of Type 2 Diabetes (RAPSODI Study). However, the 
clinical relevance of these studies was passed when the benefit/
risk ratio was evaluated by EMEA leading to the suspension of the 
drug from the market and also to the termination of the scientifically 
important and extensive research program by the manufacturer 
(www.sanofi-aventis.com). Another compound, taranabant, 
an inverse agonist at the CB1 receptor, has been developed by 
Merck® Research Laboratories and tested for the same purpose as 
rimonabant,54-56 although outcomes seem to be similar. Taranabant 
is able to reduce body weight in obese subjects, though it may 
also induce psychiatric adverse effects. In the initial clinical study, 
15% of patients experiencing psychiatric adverse effects, mainly 
anxiety, dropped out from the study56 Both a single oral dose and a 
multiple administrations study in healthy volunteers reported anxiety 
and mood changes as adverse experiences.54,55 However, it is still 
early for any meaningful analysis on the safety and efficacy of this 
drug. Considering that taranabant works by the same mechanism 
as rimonabant, more similarities than differences were expected. 
Thus, not surprisingly, Merck & Co announced the suspension of all 
research with this experimental obesity drug on October 2nd, 2008, 
since the available Phase III data showed that both efficacy and 
adverse events were dose related, with greater efficacy and more 
adverse events in the higher doses. In November 2008, Pfizer® did 
the same for another CB1 blocker, CP-945,598, which was also in 
Phase III trials for obesity.
Conclusion
The CB1 receptor antagonist rimonabant was approved for the 
treatment of obesity and soon removed from the market due to its 
psychiatric adverse effects. This drug has also been investigated 
for several other purposes such as treating diabetes, promoting 
smoking cessation and reducing alcohol consumption. So far, the 
data available are scant and have been compared to placebo, not 
with other active drugs. In any case, it already allows the conclusion 
that it may induce psychiatric side-effects, mainly anxiety and 
depression, though also agitation, eating disorders, irritability, 
aggression and insomnia. Possibly, the results discussed above 
may even be conservative and underestimate the problem, because 
in several studies psychiatric patients were not included and the 
scales used might not have detected all potential psychiatric adverse 
effects. Also, in some trials the exclusion criteria were vague, such 
as “severe psychological illness”, which might have led to an over- 
or underestimation of the psychiatric adverse effects. Additionally, 
the endpoint reported in some studies was depressed mood 
disorders, an umbrella term consisting of depression, depressive 
mood, major depression, dysthymia and depressive symptoms, 
which are disorders with different severity and clinical implications. 
Finally, other psychiatric side-effects of rimonabant have not been 
completely well investigated yet, such as psychosis, other eating 
disorders, as well as the lo ng-term psychiatric effects of such 
compound.
The mechanisms through which CB1 receptor blockade increase 
anxiety and depression remain unclear. One possibility could 
be that endocannabinoids keep an appropriate neurochemical 
balance between glutamate and gamma-aminobutyric acid (GABA), 
in such a way that blocking CB1 receptor may disrupt this set-
point and misbalance neurotransmitter activity, inhibiting GABA 
and favoring a glutamatergic tonus.25 Another mechanism could 
involve the physiological activity of anandamide at CB1 or vanilloid 
(TRPV1) receptors. Preclinical data have shown that both receptors 
are activated by anandamide, although while CB1-mediated 
mechanisms may attenuate anxiety, TRPV1 may be aversive.57 Thus, 
when CB1 receptors are blocked, anandamide would preferentially 
activate TRPV1 receptors inducing aversive reactions.
While rimonabant increases the likelihood of depressive and 
anxiogenic episodes, this effect is more pronounced in patients with 
a history of depression, suggesting that blocking CB1 receptor is 
more likely to exacerbate existing conditions rather than producing 
them in healthy individuals. In case CB1 receptor antagonists were 
to be prescribed, a careful selection of patients would be necessary 
and the presence of psychiatric disorders should be a formal 
contraindication. As in all cases of preventive medicine, health 
benefits would have been discounted heavily on the basis that the 
avoidance of death and disease in the future is less important to 
society than death and disease now.52
On the other hand, recent preclinical findings suggesting that 
cannabinoid CB1 receptor agonists and endocannabinoid enhancers 
possess antidepressant-like58 and anti-addiction59 properties, and 
the reported clinical evidence that the CB1 antagonist rimonabant 
increases the risk of depression and anxiety, support the notion 
that the endocannabinoid system represents a novel target in the 
treatment of mood disorders. Therefore, some researchers think 
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that abandoning this therapeutic avenue would be premature, 
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restrictions of this drug must be critically questioned, although 
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